Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases

References

• Morris KM, Aden DP, Knowles BB, Colten HR. Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 1982; 70: 906–913
   PubMed Web of Science ®Google Scholar
• Johnson E, Hetland G. Mononuclear phagocytes have the potential to synthesize the complete functional complement system. Scand J Immunol 1988; 27: 489–493
   Google Scholar
• Garred P, Hetland G, Mollnes TE, Stoervold G. Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts. Scand J Immunol 1990; 32: 555–560
   Google Scholar
• Montinaro V, Serra L, Perissutti S, Ranieri E, Tedesco F, Schena FP. Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines. Kidney Int 1995; 47: 829–836
   Google Scholar
• Gasque P, Fontaine M, Morgan BP. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 1995; 154: 4726–4733
   PubMed Web of Science ®Google Scholar
• Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729–777
   PubMed Web of Science ®Google Scholar
• Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743–4746
   PubMed Web of Science ®Google Scholar
• Broze GJ, Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90–93
   PubMed Web of Science ®Google Scholar
• Levin EG, Marotti KR, Santell L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA. J Biol Chem 1989; 264: 16030–16036
   PubMedGoogle Scholar
• Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–526
   PubMed Web of Science ®Google Scholar
• Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527–3561
   PubMed Web of Science ®Google Scholar
• Gulati P, Lemercier C, Guc D, Lappin D, Whaley K. Regulation of the synthesis of C1 subcomponents and C1-inhibitor. Behring Inst Mitt 1993; 196–203
   Google Scholar
• Gulati P, Guc D, Lemercier C, Lappin D, Whaley K. Expression of the components and regulatory proteins of the classical pathway of complement in normal and diseased synovium. Rheumatol Int 1994; 14: 13–19
   Google Scholar
• Warren HB, Pantazis P, Davies PF. The third component of complement is transcribed and secreted by cultured human endothelial cells. Am J Pathol 1987; 129: 9–13
   PubMed Web of Science ®Google Scholar
• Dauchel H, Julen N, Lemercier C, Daveau M, Ozanne D, Fontaine M, Ripoche J. Expression of complement alternative pathway proteins by endothelial cells. Differential regulation by interleukin 1 and glucocorticoids. Eur J Immunol 1990; 20: 1669–1675
   Google Scholar
• Langeggen H, Pausa M, Johnson E, Casarsa C, Tedesco F. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121: 69–76
   PubMed Web of Science ®Google Scholar
• Wurzner R, Joysey VC, Lachmann PJ. Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. J Immunol 1994; 152: 4624–4629
   Google Scholar
• Johnson E, Hetland G. Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro. Scand J Immunol 1991; 33: 667–671
   Google Scholar
• Langeggen H, Berge KE, Macor P, Fischetti F, Tedesco F, Hetland G, Berg K, Johnson E. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. Apmis 2001; 109: 73–78
   Google Scholar
• Brooimans RA, van der Ark AA, Buurman WA, van Es LA, Daha MR. Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-gamma and IL-1. J Immunol 1990; 144: 3835–3840
   PubMedGoogle Scholar
• Berge V, Johnson E, Berge KE. Interleukin-1 alpha, interleukin 6 and tumor necrosis factor alpha increase the synthesis and expression of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro. Apmis 1996; 104: 213–219
   Google Scholar
• Ueki A, Sai T, Oka H, Tabata M, Hosokawa K, Mochizuki Y. Biosynthesis and secretion of the third component of complement by human endothelial cells in vitro. Immunology 1987; 61: 11–14
   PubMed Web of Science ®Google Scholar
• Vakeva A, Meri S. Complement activation and regulator expression after anoxic injury of human endothelial cells. Apmis 1998; 106: 1149–1156
   PubMed Web of Science ®Google Scholar
• Sheerin NS, Zhou W, Adler S, Sacks SH. TNF-alpha regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells. Kidney Int 1997; 51: 703–710
   Google Scholar
• Vastag M, Skopal J, Kramer J, Kolev K, Voko Z, Csonka E, Machovich R, Nagy Z. Endothelial cells cultured from human brain microvessels produce complement proteins factor H, factor B, C1 inhibitor, and C4. Immunobiology 1998; 199: 5–13
   Google Scholar
• Ripoche J, Mitchell JA, Erdei A, Madin C, Moffatt B, Mokoena T, Gordon S, Sim RB. Interferon gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J Exp Med 1988; 168: 1917–1922
   Google Scholar
• Coulpier M, Andreev S, Lemercier C, Dauchel H, Lees O, Fontaine M, Ripoche J. Activation of the endothelium by IL-1 alpha and glucocorticoids results in major increase of complement C3 and factor B production and generation of C3a. Clin Exp Immunol 1995; 101: 142–149
   Google Scholar
• Collard CD, Vakeva A, Bukusoglu C, Zund G, Sperati CJ, Colgan SP, Stahl GL. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation 1997; 96: 326–333
   PubMed Web of Science ®Google Scholar
• Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL. Complement activation after oxidative stress: Role of the lectin complement pathway. Am J Pathol 2000; 156: 1549–1556
   PubMed Web of Science ®Google Scholar
• Fleming SD, Egan RP, Chai C, Girardi G, Holers VM, Salmon J, Monestier M, Tsokos GC. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol 2004; 173: 7055–7061
   PubMedGoogle Scholar
• Mold C, Morris CA. Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation. Immunology 2001; 102: 359–364
   PubMed Web of Science ®Google Scholar
• Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001; 38: 189–197
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J, Tijsma O, Hack EC, Daha MR, Roos A. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003; 33: 465–473
   PubMed Web of Science ®Google Scholar
• Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001; 166: 3231–3239
   PubMed Web of Science ®Google Scholar
• Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, Recht PA, Golden B, Cronstein BN. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA 1995; 92: 8378–8382
   PubMed Web of Science ®Google Scholar
• Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94: 1147–1155
   PubMed Web of Science ®Google Scholar
• Albrecht EA, Chinnaiyan AM, Varambally S, Kumar-Sinha C, Barrette TR, Sarma JV, Ward PA. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 2004; 164: 849–859
   PubMed Web of Science ®Google Scholar
• Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995; 155: 1434–1441
   PubMed Web of Science ®Google Scholar
• Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264: 9053–9060
   PubMed Web of Science ®Google Scholar
• Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619–1627
   PubMed Web of Science ®Google Scholar
• Dobrina A, Pausa M, Fischetti F, Bulla R, Vecile E, Ferrero E, Mantovani A, Tedesco F. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 2002; 99: 185–192
   Google Scholar
• Casarsa C, De Luigi A, Pausa M, De Simoni MG, Tedesco F. Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain. Eur J Immunol 2003; 33: 1260–1270
   PubMedGoogle Scholar
• van den Berg RH, Faber-Krol MC, Sim RB, Daha MR. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 1998; 161: 6924–6930
   PubMed Web of Science ®Google Scholar
• Czermak BJ, Sarma V, Bless NM, Schmal H, Friedl HP, Ward PA. In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol 1999; 162: 2321–2325
   PubMed Web of Science ®Google Scholar
• Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996; 149: 953–961
   PubMed Web of Science ®Google Scholar
• Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997; 150: 2019–2031
   PubMed Web of Science ®Google Scholar
• Halperin JA, Taratuska A, Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 1993; 91: 1974–1978
   Google Scholar
• Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985–992
   PubMed Web of Science ®Google Scholar
• Selvan RS, Kapadia HB, Platt JL. Complement-induced expression of chemokine genes in endothelium: Regulation by IL-1-dependent and -independent mechanisms. J Immunol 1998; 161: 4388–4395
   Google Scholar
• Platt JL, Dalmasso AP, Lindman BJ, Ihrcke NS, Bach FH. The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur J Immunol 1991; 21: 2887–2890
   PubMed Web of Science ®Google Scholar
• Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394–398
   PubMed Web of Science ®Google Scholar
• Christiansen VJ, Sims PJ, Hamilton KK. Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 164–171
   Google Scholar
• Hamilton KK, Ji Z, Rollins S, Stewart BH, Sims PJ. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: Neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 1990; 76: 2572–2577
   PubMed Web of Science ®Google Scholar
• Lupia E, Del Sorbo L, Bergerone S, Emanuelli G, Camussi G, Montrucchio G. The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils. Immunology 2003; 109: 557–563
   Google Scholar
• Peerschke EI, Malhotra R, Ghebrehiwet B, Reid KB, Willis AC, Sim RB. Isolation of a human endothelial cell C1q receptor (C1qR). J Leukoc Biol 1993; 53: 179–184
   Google Scholar
• Peerschke EI, Smyth SS, Teng EI, Dalzell M, Ghebrehiwet B. Human umbilical vein endothelial cells possess binding sites for the globular domain of C1q. J Immunol 1996; 157: 4154–4158
   PubMed Web of Science ®Google Scholar
• Malhotra R, Willis AC, Jensenius JC, Jackson J, Sim RB. Structure and homology of human C1q receptor (collectin receptor). Immunology 1993; 78: 341–348
   Google Scholar
• Malhotra R, Thiel S, Reid KB, Sim RB. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med 1990; 172: 955–959
   PubMed Web of Science ®Google Scholar
• Ghebrehiwet B, Silvestri L, McDevitt C. Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization. J Exp Med 1984; 160: 1375–1389
   Google Scholar
• Ghebrehiwet B, Lim BL, Peerschke EI, Willis AC, Reid KB. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular “heads” of C1q. J Exp Med 1994; 179: 1809–1821
   PubMed Web of Science ®Google Scholar
• Feng X, Tonnesen MG, Peerschke EI, Ghebrehiwet B. Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. J Immunol 2002; 168: 2441–2448
   PubMedGoogle Scholar
• Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781–795
   PubMed Web of Science ®Google Scholar
• Van Beek J, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, Fontaine M. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 2000; 161: 373–382
   PubMed Web of Science ®Google Scholar
• Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17: 1003–1014
   PubMed Web of Science ®Google Scholar
• Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 2002; 169: 2102–2110
   PubMed Web of Science ®Google Scholar
• Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A, Haviland JC, Parks WC, Perlmutter DH, Wetsel RA. Cellular expression of the C5a anaphylatoxin receptor (C5aR): Demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 1995; 154: 1861–1869
   PubMed Web of Science ®Google Scholar
• Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Gotze O, Morgan BP. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol 1995; 155: 4882–4889
   PubMed Web of Science ®Google Scholar
• Zwirner J, Fayyazi A, Gotze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999; 36: 877–884
   Google Scholar
• Laudes IJ, Chu JC, Huber-Lang M, Guo RF, Riedemann NC, Sarma JV, Mahdi F, Murphy HS, Speyer C, Lu KT, Lambris JD, Zetoune FS, Ward PA. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002; 169: 5962–5970
   PubMed Web of Science ®Google Scholar
• Rollins TE, Siciliano S, Kobayashi S, Cianciarulo DN, Bonilla-Argudo V, Collier K, Springer MS. Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex. Proc Natl Acad Sci USA 1991; 88: 971–975
   Google Scholar
• Norgauer J, Dobos G, Kownatzki E, Dahinden C, Burger R, Kupper R, Gierschik P. Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G protein. Eur J Biochem 1993; 217: 289–294
   PubMedGoogle Scholar
• Lucchesi BR, Kilgore KS. Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology 1997; 38: 27–42
   Google Scholar
• Mugge A, Lopez JA, Heistad DD, Lichtlen PR. Vasoconstriction in response to activated leukocytes: Implications for vasospasm. Eur Heart J 1993; 14(Suppl I)87–92
   Google Scholar
• Fischetti F, Carretta R, Borotto G, Durigutto P, Bulla R, Meroni PL, Tedesco F. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 2004; 135: 186–193
   PubMed Web of Science ®Google Scholar
• DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and ransendothelial migration in vitro and in vivo. J Immunol 1999; 162: 1127–1136
   PubMed Web of Science ®Google Scholar
• Bossi F, Fischetti F, Pellis V, Bulla R, Ferrero E, Mollnes TE, Regoli D, Tedesco F. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 2004; 173: 6921–6927
   PubMed Web of Science ®Google Scholar
• Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807–1814
   PubMed Web of Science ®Google Scholar
• Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809–3814
   PubMed Web of Science ®Google Scholar
• Suttorp N, Seeger W, Zinsky S, Bhakdi S. Complement complex C5b-8 induces PGI2 formation in cultured endothelial cells. Am J Physiol 1987; 253: C13–C21
   Google Scholar
• Bustos M, Coffman TM, Saadi S, Platt JL. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. J Clin Invest 1997; 100: 1150–1158
   PubMed Web of Science ®Google Scholar
• Brooimans RA, Hiemstra PS, van der Ark AA, Sim RB, van Es LA, Daha MR. Biosynthesis of complement factor H by human umbilical vein endothelial cells. Regulation by T cell growth factor and IFN-gamma. J Immunol 1989; 142: 2024–2030
   Google Scholar
• Julen N, Dauchel H, Lemercier C, Sim RB, Fontaine M, Ripoche J. In vitro biosynthesis of complement factor I by human endothelial cells. Eur J Immunol 1992; 22: 213–217
   Google Scholar
• Berge V, Johnson E, Hogasen K, Hetland G. Human umbilical vein endothelial cells synthesize S-protein (vitronectin) in vitro. Scand J Immunol 1992; 36: 119–123
   Google Scholar
• Berge V, Johnson E, Hogasen K. Clusterin and the terminal complement pathway synthesized by human umbilical vein endothelial cells are closely linked when detected on co-cultured agarose beads. Apmis 1997; 105: 17–24
   Google Scholar
• Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181–1190
   PubMed Web of Science ®Google Scholar
• Asch AS, Kinoshita T, Jaffe EA, Nussenzweig V. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 1986; 163: 221–226
   PubMed Web of Science ®Google Scholar
• McNearney T, Ballard L, Seya T, Atkinson JP. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J Clin Invest 1989; 84: 538–545
   Google Scholar
• Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 1999; 94: 1673–1682
   PubMed Web of Science ®Google Scholar
• Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: A mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum 2001; 44: 138–150
   Google Scholar
• Tsuji S, Kaji K, Nagasawa S. Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface. J Immunol 1994; 152: 1404–1410
   Google Scholar
• Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 2000; 96: 2784–2792
   Google Scholar
• Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PW, Li RK, Mickle DA, Verma S. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004; 109: 833–836
   PubMedGoogle Scholar
• Venneker GT, van den Hoogen FH, Boerbooms AM, Bos JD, Asghar SS. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab Invest 1994; 70: 830–835
   Google Scholar
• Morgan B, Harris C. Complement regulatory proteins. Academic Press, London 1999
   Google Scholar
• Langeggen H, Berge KE, Johnson E, Hetland G. Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro. Inflammation 2002; 26: 103–110
   PubMedGoogle Scholar
• Hindmarsh EJ, Marks RM. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol 1998; 28: 1052–1062
   PubMed Web of Science ®Google Scholar
• Mason JC, Lidington EA, Ahmad SR, Haskard DO. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol 2002; 282: C578–C587
   Google Scholar
• Collard CD, Bukusoglu C, Agah A, Colgan SP, Reenstra WR, Morgan BP, Stahl GL. Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am J Physiol 1999; 276: C450–C458
   Google Scholar
• Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035–1050
   PubMed Web of Science ®Google Scholar
• Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981; 46: 110–119
   PubMed Web of Science ®Google Scholar
• Hammar SP, Bloomer HA, McCloskey D. Adult hemolytic uremic syndrome with renal arteriolar deposition of IgM and C3. Am J Clin Pathol 1978; 70: 434–439
   Google Scholar
• Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, Remuzzi G. Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93: 443–452
   PubMed Web of Science ®Google Scholar
• Ren G, Hack BK, Minto AW, Cunningham PN, Alexander JJ, Haas M, Quigg RJ. A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin Immunol 2002; 103: 43–53
   PubMed Web of Science ®Google Scholar
• Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: Report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15: 787–795
   PubMed Web of Science ®Google Scholar
• Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555–563
   PubMed Web of Science ®Google Scholar
• Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542–1547
   PubMed Web of Science ®Google Scholar
• Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003; 100: 12966–12971
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41: e84
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Heinen S, Jozsi M, Skerka C. Complement and diseases: Defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97–106
   PubMed Web of Science ®Google Scholar
• Hogasen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95: 1054–1061
   PubMed Web of Science ®Google Scholar
• Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31: 424–428
   PubMed Web of Science ®Google Scholar
• Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, Halperin J. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 2000; 97: 5450–5455
   PubMed Web of Science ®Google Scholar
• Triolo G, Giardina E, Casiglia D, Scarantino G, Bompiani GD. Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor. Clin Exp Immunol 1991; 84: 53–58
   Google Scholar
• Falk RJ, Sisson SP, Dalmasso AP, Kim Y, Michael AF, Vernier RL. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 1987; 9: 121–128
   Google Scholar
• Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh epidemiology of diabetes complications study. Diabetes 1999; 48: 1454–1458
   PubMed Web of Science ®Google Scholar
• Accardo-Palumbo A, Triolo G, Colonna-Romano G, Potestio M, Carbone M, Ferrante A, Giardina E, Caimi G. Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells. Diabetologia 2000; 43: 1039–1047
   PubMedGoogle Scholar
• Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M, Hays AP, Halperin JA. Glycation inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004; 53: 2653–2661
   PubMed Web of Science ®Google Scholar
• Uesugi N, Sakata N, Nangaku M, Abe M, Horiuchi S, Hisano S, Iwasaki H. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: Glycoxidation-mediated local complement activation. Am J Kidney Dis 2004; 44: 224–238
   Google Scholar
• Hughes GR. Hughes' syndrome: The antiphospholipid syndrome. A historical view. Lupus 1998; 7(Suppl 2)S1–S4
   PubMedGoogle Scholar
• Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am 2001; 27: 587–602
   PubMed Web of Science ®Google Scholar
• Pierangeli SS, Gharavi AE, Harris EN. Experimental thrombosis and antiphospholipid antibodies: New insights. J Autoimmun 2000; 15: 241–247
   Google Scholar
• Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF, Arnout J. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157–162
   PubMed Web of Science ®Google Scholar
• Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni P, Tedesco F. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340–2346
   PubMed Web of Science ®Google Scholar
• Cervera R, Asherson RA, Acevedo ML, Gomez-Puerta JA, Espinosa G, De La Red G, Gil V, Ramos-Casals M, Garcia-Carrasco M, Ingelmo M, Font J. Antiphospholipid syndrome associated with infections: Clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004; 63: 1312–1317
   PubMed Web of Science ®Google Scholar
• Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2003; 5: 395–400
   PubMedGoogle Scholar
• Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 2120–2124
   Google Scholar
• Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: In vitro and in vivo studies. Eur J Immunol 2002; 32: 2773–2782
   PubMed Web of Science ®Google Scholar
• Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005; 42: 87–97
   PubMed Web of Science ®Google Scholar
• Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985; 57: 163–177
   PubMed Web of Science ®Google Scholar
• Niculescu F, Hugo F, Rus HG, Vlaicu R, Bhakdi S. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. Clin Exp Immunol 1987; 69: 477–483
   PubMedGoogle Scholar
• Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, Walev I, Wieland E. On the pathogenesis of atherosclerosis: Enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182: 1959–1971
   PubMed Web of Science ®Google Scholar
• Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18: 369–378
   PubMed Web of Science ®Google Scholar
• Rus HG, Niculescu F, Constantinescu E, Cristea A, Vlaicu R. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis 1986; 61: 35–42
   Google Scholar
• Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989; 60: 747–754
   PubMedGoogle Scholar
• Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386–1392
   PubMed Web of Science ®Google Scholar
• Lopes-Virella MF, Virella G. Atherosclerosis and autoimmunity. Clin Immunol Immunopathol 1994; 73: 155–167
   Google Scholar
• Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218–1226
   PubMed Web of Science ®Google Scholar
• Mayr M, Metzler B, Kiechl S, Willeit J, Schett G, Xu Q, Wick G. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999; 99: 1560–1566
   PubMed Web of Science ®Google Scholar
• Schett G, Xu Q, Amberger A, Van der Zee R, Recheis H, Willeit J, Wick G. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 1995; 96: 2569–2577
   PubMed Web of Science ®Google Scholar
• Wieland E, Dorweiler B, Bonitz U, Lieser S, Walev I, Bhakdi S. Complement activation by oxidatively modified low-density lipoproteins. Eur J Clin Invest 1999; 29: 835–841
   Google Scholar
• Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172: 547–557
   PubMed Web of Science ®Google Scholar
• Hamilton KK, Sims PJ. The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells. J Clin Invest 1991; 88: 1833–1840
   Google Scholar
• Geertinger P, Sorensen H. On the reduced atherogenic effects of cholesterol feeding on rabbits with congenital complement (C6) deficiency. Artery 1977; 1: 177–184
   Google Scholar
• Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, Oelert H, Metz J, Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18: 1790–1795
   PubMed Web of Science ®Google Scholar
• Patel S, Thelander EM, Hernandez M, Montenegro J, Hassing H, Burton C, Mundt S, Hermanowski-Vosatka A, Wright SD, Chao YS, Detmers PA. ApoE(−/−) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 2001; 286: 164–170
   Google Scholar
• Persson L, Boren J, Robertson AK, Wallenius V, Hansson GK, Pekna M. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor−/− mice. Arterioscler Thromb Vasc Biol 2004; 24: 1062–1067
   PubMedGoogle Scholar
• Claudy A. Pathogenesis of leukocytoclastic vasculitis. Eur J Dermatol 1998; 8: 75–79
   PubMedGoogle Scholar
• Boom BW, Mommaas AM, Daha MR, Vermeer BJ. Decreased expression of decay-accelerating factor on endothelial cells of immune complex-mediated vasculitic skin lesions. J Dermatol Sci 1991; 2: 308–315
   Google Scholar
• Dauchel H, Joly P, Delpech A, Thomine E, Sauger F, Le Loet X, Lauret P, Tron F, Fontaine M, Ripoche J. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers. Clin Exp Immunol 1993; 92: 274–283
   Google Scholar
• Kawana S, Shen GH, Kobayashi Y, Nishiyama S. Membrane attack complex of complement in Henoch-Schonlein purpura skin and nephritis. Arch Dermatol Res 1990; 282: 183–187
   PubMedGoogle Scholar
• Boom BW, Mommaas M, Daha MR, Vermeer BJ. Complement-mediated endothelial cell damage in immune complex vasculitis of the skin: Ultrastructural localization of the membrane attack complex. J Invest Dermatol 1989; 93: 68S–72S
   Google Scholar
• Leung DY, Collins T, Lapierre LA, Geha RS, Pober JS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest 1986; 77: 1428–1435
   PubMed Web of Science ®Google Scholar
• Fujieda M, Oishi N, Kurashige T. Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment. Clin Exp Immunol 1997; 107: 120–126
   PubMed Web of Science ®Google Scholar
• Ronco P, Verroust P, Mignon F, Kourilsky O, Vanhille P, Meyrier A, Mery JP, Morel-Maroger L. Immunopathological studies of polyarteritis nodosa and Wegener's granulomatosis: A report of 43 patients with 51 renal biopsies. Q J Med 1983; 52: 212–223
   Google Scholar
• Holmen C, Christensson M, Pettersson E, Bratt J, Stjarne P, Karrar A, Sumitran-Holgersson S. Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies. Kidney Int 2004; 66: 1049–1060
   PubMed Web of Science ®Google Scholar
• Tripathy NK, Upadhyaya S, Sinha N, Nityanand S. Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu's arteritis. J Rheumatol 2001; 28: 805–808
   PubMed Web of Science ®Google Scholar
• Gabrielli A, Zhang ZX, Cherubini G, Candela M, Savoldi S, Manzin A, Clementi M, Amoroso A, Sallberg M. Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol 1996; 105: 59–64
   Google Scholar
• Franklin EC. The role of cryoglobulins and immune complexes in vasculitis. J Allergy Clin Immunol 1980; 66: 269–273
   PubMedGoogle Scholar
• Kaplanski G, Maisonobe T, Marin V, Gres S, Robitail S, Farnarier C, Harle JR, Piette JC, Cacoub P. Vascular cell adhesion molecule-1 (VCAM-1) plays a central role in the pathogenesis of severe forms of vasculitis due to hepatitis C-associated mixed cryoglobulinemia. J Hepatol 2005; 42: 334–340
   PubMed Web of Science ®Google Scholar
• Trendelenburg M, Fossati-Jimack L, Cortes-Hernandez J, Turnberg D, Lewis M, Izui S, Cook HT, Botto M. The role of complement in cryoglobulin-induced immune complex glomerulonephritis. J Immunol 2005; 175: 6909–6914
   Google Scholar
• Werder M, Truniger B. Hypocomplementaemic urticarial vasculitis. Nephrol Dial Transplant 1997; 12: 1278–1279
   Google Scholar
• Trendelenburg M, Courvoisier S, Spath PJ, Moll S, Mihatsch M, Itin P, Schifferli JA. Hypocomplementemic urticarial vasculitis or systemic lupus erythematosus?. Am J Kidney Dis 1999; 34: 745–751
   Google Scholar
• Wisnieski JJ, Jones SM. Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus. J Immunol 1992; 148: 1396–1403
   PubMed Web of Science ®Google Scholar